Clinical Trial Results: Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ultra-low dose naloxone to mitigate remifentanil-induced hyperalgesia; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperalgesia

Drugs mentioned

• Naloxone (ultra-low dose) (naloxone)
• Remifentanil (remifentanil)

Snippet

Sponsor: University of California, Irvine | Conditions: Hyperalgesia | Phase 2 | Status: TERMINATED | Results posted: 2026-06-04